Literature DB >> 17412603

Effects of gender on nigral gene expression and parkinson disease.

Ippolita Cantuti-Castelvetri1, Christine Keller-McGandy, Bérengère Bouzou, Georgios Asteris, Timothy W Clark, Matthew P Frosch, David G Standaert.   

Abstract

To identify gene expression patterns in human dopamine (DA) neurons in the substantia nigra pars compacta (SNc) of male and female control and Parkinson disease (PD) patients, we harvested DA neurons from frozen SNc from 16 subjects (4 male PDs, 4 female PDs, 4 male and 4 female controls) using Laser Capture microdissection and microarrays. We assessed for enrichment of functional categories with a hypergeometric distribution. The data were validated with QPCR. We observed that gender has a pervasive effect on gene expression in DA neurons. Genes upregulated in females relative to males are mainly involved in signal transduction and neuronal maturation, while in males some of the upregulated genes (alpha-synuclein and PINK1) were previously implicated in the pathogenesis of PD. In females with PD we found alterations in genes with protein kinase activity, genes involved in proteolysis and WNT signaling pathway, while in males with PD there were alterations in protein-binding proteins and copper-binding proteins. Our data reveal broad gender-based differences in gene expression in human dopaminergic neurons of SNc that may underlie the predisposition of males to PD. Moreover, we show that gender influences the response to PD, suggesting that the nature of the disease and the response to treatment may be gender-dependent.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17412603      PMCID: PMC2435483          DOI: 10.1016/j.nbd.2007.02.009

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  67 in total

1.  Gene ontology: tool for the unification of biology. The Gene Ontology Consortium.

Authors:  M Ashburner; C A Ball; J A Blake; D Botstein; H Butler; J M Cherry; A P Davis; K Dolinski; S S Dwight; J T Eppig; M A Harris; D P Hill; L Issel-Tarver; A Kasarskis; S Lewis; J C Matese; J E Richardson; M Ringwald; G M Rubin; G Sherlock
Journal:  Nat Genet       Date:  2000-05       Impact factor: 38.330

2.  Isolation of sex-specific cDNAs from fetal mouse brain using mRNA differential display and representational difference analysis.

Authors:  A Eriksson; C Wahlestedt; K Nordqvist
Journal:  Brain Res Mol Brain Res       Date:  1999-12-10

3.  Gender-specific gene expression in post-mortem human brain: localization to sex chromosomes.

Authors:  Marquis P Vawter; Simon Evans; Prabhakara Choudary; Hiroaki Tomita; Jim Meador-Woodruff; Margherita Molnar; Jun Li; Juan F Lopez; Rick Myers; David Cox; Stanley J Watson; Huda Akil; Edward G Jones; William E Bunney
Journal:  Neuropsychopharmacology       Date:  2004-02       Impact factor: 7.853

4.  A benchmark for Affymetrix GeneChip expression measures.

Authors:  Leslie M Cope; Rafael A Irizarry; Harris A Jaffee; Zhijin Wu; Terence P Speed
Journal:  Bioinformatics       Date:  2004-02-12       Impact factor: 6.937

5.  A fetal risk factor for Parkinson's disease.

Authors:  Brian K Barlow; Eric K Richfield; Deborah A Cory-Slechta; Mona Thiruchelvam
Journal:  Dev Neurosci       Date:  2004 Jan-Feb       Impact factor: 2.984

6.  Estrogen reduces acute striatal dopamine responses in vivo to the neurotoxin MPP+ in female, but not male rats.

Authors:  K A Disshon; D E Dluzen
Journal:  Brain Res       Date:  2000-06-16       Impact factor: 3.252

Review 7.  Sex dimorphisms in the neuroprotective effects of estrogen in an animal model of Parkinson's disease.

Authors:  Glenda E Gillies; Hilary E Murray; David Dexter; Simon McArthur
Journal:  Pharmacol Biochem Behav       Date:  2004-07       Impact factor: 3.533

8.  Pael-R is accumulated in Lewy bodies of Parkinson's disease.

Authors:  Tetsuro Murakami; Mikio Shoji; Yuzuru Imai; Haruhisa Inoue; Takeshi Kawarabayashi; Etsuro Matsubara; Yasuo Harigaya; Atsushi Sasaki; Ryosuke Takahashi; Koji Abe
Journal:  Ann Neurol       Date:  2004-03       Impact factor: 10.422

9.  Risk of Parkinson disease in women: effect of reproductive characteristics.

Authors:  P Ragonese; M D'Amelio; G Salemi; P Aridon; M Gammino; A Epifanio; L Morgante; G Savettieri
Journal:  Neurology       Date:  2004-06-08       Impact factor: 9.910

10.  Confirming microarray data--is it really necessary?

Authors:  John C Rockett; Gary M Hellmann
Journal:  Genomics       Date:  2004-04       Impact factor: 5.736

View more
  103 in total

1.  PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease.

Authors:  Bin Zheng; Zhixiang Liao; Joseph J Locascio; Kristen A Lesniak; Sarah S Roderick; Marla L Watt; Aron C Eklund; Yanli Zhang-James; Peter D Kim; Michael A Hauser; Edna Grünblatt; Linda B Moran; Silvia A Mandel; Peter Riederer; Renee M Miller; Howard J Federoff; Ullrich Wüllner; Spyridon Papapetropoulos; Moussa B Youdim; Ippolita Cantuti-Castelvetri; Anne B Young; Jeffery M Vance; Richard L Davis; John C Hedreen; Charles H Adler; Thomas G Beach; Manuel B Graeber; Frank A Middleton; Jean-Christophe Rochet; Clemens R Scherzer
Journal:  Sci Transl Med       Date:  2010-10-06       Impact factor: 17.956

2.  Effects of gender on gene expression in the blood of ischemic stroke patients.

Authors:  Yingfang Tian; Boryana Stamova; Glen C Jickling; Dazhi Liu; Bradley P Ander; Cheryl Bushnell; Xinhua Zhan; Ryan R Davis; Piero Verro; William C Pevec; Nasim Hedayati; David L Dawson; Jane Khoury; Edward C Jauch; Arthur Pancioli; Joseph P Broderick; Frank R Sharp
Journal:  J Cereb Blood Flow Metab       Date:  2011-12-14       Impact factor: 6.200

Review 3.  Do you know the sex of your cells?

Authors:  Kalpit Shah; Charles E McCormack; Neil A Bradbury
Journal:  Am J Physiol Cell Physiol       Date:  2013-11-06       Impact factor: 4.249

4.  Improved RNA preservation for immunolabeling and laser microdissection.

Authors:  Amanda L Brown; Doug W Smith
Journal:  RNA       Date:  2009-10-22       Impact factor: 4.942

Review 5.  Gender differences in Parkinson's disease: focus on plasma α-synuclein.

Authors:  Giovanni Caranci; Paola Piscopo; Roberto Rivabene; Anna Traficante; Barbara Riozzi; Anna Elisa Castellano; Stefano Ruggieri; Nicola Vanacore; Annamaria Confaloni
Journal:  J Neural Transm (Vienna)       Date:  2013-01-18       Impact factor: 3.575

6.  miR-126 contributes to Parkinson's disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling.

Authors:  Woori Kim; Yenarae Lee; Noah D McKenna; Ming Yi; Filip Simunovic; Yulei Wang; Benjamin Kong; Robert J Rooney; Hyemyung Seo; Robert M Stephens; Kai C Sonntag
Journal:  Neurobiol Aging       Date:  2014-01-24       Impact factor: 4.673

7.  Sex-specific neuroprotection by inhibition of the Y-chromosome gene, SRY, in experimental Parkinson's disease.

Authors:  Joohyung Lee; Paulo Pinares-Garcia; Hannah Loke; Seungmin Ham; Eric Vilain; Vincent R Harley
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-01       Impact factor: 11.205

8.  Mitochondrial DNA haplogroups and subhaplogroups are associated with Parkinson's disease risk in a Polish PD cohort.

Authors:  Katarzyna Gaweda-Walerych; Aleksandra Maruszak; Krzysztof Safranow; Monika Bialecka; Gabriela Klodowska-Duda; Krzysztof Czyzewski; Jaroslaw Slawek; Monika Rudzinska; Maria Styczynska; Grzegorz Opala; Marek Drozdzik; Jeffrey A Canter; Maria Barcikowska; Cezary Zekanowski
Journal:  J Neural Transm (Vienna)       Date:  2008-09-23       Impact factor: 3.575

Review 9.  The Role of Sex and Sex Hormones in Neurodegenerative Diseases.

Authors:  Elisabetta Vegeto; Alessandro Villa; Sara Della Torre; Valeria Crippa; Paola Rusmini; Riccardo Cristofani; Mariarita Galbiati; Adriana Maggi; Angelo Poletti
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

10.  Parkinson's Disease Master Regulators on Substantia Nigra and Frontal Cortex and Their Use for Drug Repositioning.

Authors:  D M Vargas; M A De Bastiani; R B Parsons; F Klamt
Journal:  Mol Neurobiol       Date:  2020-11-19       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.